epithelial cells in humans, mice, rats and guinea pigs. Upon activation, PARs can enhance the formation of prostanoids, especially prostaglandin E 2 , resulting in tracheal and bronchial smooth muscle relaxation (Cocks et al., 1999a; Chow et al., 2000; Ricciardolo et al., 2000; Lan et al., 2001 ).
In contrast, activation of PAR-1 and/or PAR-2 present in airway smooth muscle cells can also cause contractile responses (Cocks et al., 1999a; Ricciardolo et al., 2000; Schmidlin et al., 2001) . Although a protective role for epithelial PAR-2 in the trachea or bronchus has been suggested (Cocks et al., 1999a; Cicala et al., 2001b; Moffatt et al., 2002) , there is also much evidence for a pro-inflammatory role for PAR-2 in the respiratory system (Vliagoftis et al., 2000; Sun et al., 2001; Schmidlin et al., 2002) . Clinical evidence suggests that PAR-2 is up-regulated in the respiratory epithelium of patients with asthma (Knight et al., 2001 ). Since PAR-2 antagonists have yet to be discovered, the potential physiological functions of PAR-2 have been assessed in large part with the use of receptor-selective activating peptides along with their scrambled sequence inactive controls. As an alternative, the actions of such peptides in PAR-deficient animals has proved revealing (Vergnolle et al., 2001 ; (Fig. 4) . The p38 MAP kinase inhibitor SB203580 at 10 µ M also exerted almost complete and partial inhibition in the trachea and bronchus, respectively (Fig. 4) . In contrast, the tyrosine kinase inhibitor genistein at 30 µ M or the protein kinase C inhibitor GF109203X at 1 µ M exhibited no significant inhibitory effects in the trachea or bronchus (Fig. 4) .
Effects of inhibitors of iPLA 2 , MEK and p38 MAP kinase on the tracheal or
This article has not been copyedited and formatted. The final version may differ from this version. Prostaglandin E 2 at 25 nM elicited relaxation responses in the tracheal and bronchial strips from the mice. Neither PD98059 nor SB203580 blocked the relaxant effects of prostaglandin E 2 in the trachea and/or bronchus ( Fig. 5) , indicating an involvement of MEK and p38 MAP kinase upstream of prostaglandin E 2 formation. In contrast, BEL significantly (P < 0.05) reduced the prostaglandin E 2 -evoked relaxation by approximately 30% in the tracheal preparation; the relaxation responses caused by prostaglandin E 2 in the absence and presence of BEL were: 47.8±3.1 and 33.7±3.6 (n = 6).
Effects of desensitization of PAR-2 and/or PAR-1 on the trypsin-evoked tracheal and bronchial relaxation in ddY mice. To examine whether PAR-2 and/or PAR-1 mediate trypsin-evoked airway relaxation, we performed desensitization experiments. The trypsin-evoked relaxation response was reduced slightly by desensitization of PAR-2 or PAR-1, and more dramatically by desensitization of both PAR-2 and PAR-1 in ddY mouse bronchus ( Fig. 6a and Fig.   6b , bottom). The EC 50 value of trypsin was significantly elevated by desensitization of both PAR-2 and PAR-1 in the bronchus, as compared with the control and that after desensitization of PAR-2 or PAR-1 alone (Table 2 ). In the tracheal preparation from ddY mice, desensitization of PAR-2 and/or This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7a ). As observed in ddY mice, SLIGRL-NH 2 produced concentration-dependent relaxation in both trachea and bronchus from wild-type C57BL/6 mice ( Fig. 7b) , the potency being much greater in the latter preparation than the former (Table 3 ). In contrast, the potency of 2f-LIGRL-NH 2 was a little greater in the trachea than the bronchus ( Fig. 7b and Table 3 ). Since SLIGRL-NH 2 , but not 2f-LIGRL-NH 2 , is degraded by aminopeptidase (Kawabata et al., 2004a) , the relaxant effects of SLIGRL-NH 2 were also tested in the presence of amastatin, an aminopeptidase inhibitor. The concentration-relaxation curves for SLIGRL-NH 2 in the trachea and bronchus were left-shifted by pretreatment with amastatin ( Fig. 7b) , whereas the potency was still greater in the latter preparation than the former (Table 3) . Thus, the discrepancy that the potencies of SLIGRL-NH 2 and 2f-LIGRL-NH 2 are This article has not been copyedited and formatted. The final version may differ from this version. 'bronchus > trachea' and 'trachea > bronchus', respectively, in C57BL/6 mice (Table 3) , as in ddY mice (see Fig. 1 and Table 1) , cannot be explained by tissue differences in the expression levels of aminopeptidase. Of importance is that neither SLIGRL-NH 2 nor 2f-LIGRL-NH 2 caused relaxant responses either in the trachea or bronchus of PAR-2-knockout mice of C57BL/6 background ( Fig.   7 ).
Trypsin evoked tracheal and bronchial relaxation in wild-type C57BL/6 mice, the potency being 100-fold greater in the bronchial preparation than the trachea ( Fig. 7b and Table 3 ), in agreement with the data in ddY mice (see Fig. 1 and Table 1 ). The concentration-response curve for trypsin in C57BL/6 mouse trachea was not biphasic (Fig. 7b) , in contrast to that in ddY mouse trachea (see Fig. 1 ) PAR-2-independent relaxant effects of trypsin were also observed in the trachea and bronchus from PAR-2-knockout mice, but at much higher enzyme concentrations ( Fig. 7b and Table 3 ).
As shown in ddY mouse preparations ( 
Effects of desensitization of PAR-2 and/or PAR-1 on the trypsin-evoked tracheal and
bronchial relaxation in wild-type C57BL/6 mice. In wild-type C57BL/6 mouse trachea and bronchus, desensitization of PAR-2 by two applications of SLIGRL-NH 2 at 100 µ M reduced the relaxant effect of trypsin, particularly at low concentrations, in the bronchus (Fig. 8a and 8b, bottom) and trachea (Fig. 8b, top) , although statistically significant difference in EC 50 values was detected in the bronchus, but not the trachea. (Table 4 ) Interestingly, the difference between relaxant effects of trypsin in the control and PAR-2-desensitized preparations ( Fig. 8b ) was similar to that between the responses in the wild-type and PAR-2-knockout mice (see Fig. 7b ). In contrast, PAR-1 desensitization by two applications of TFLLR-NH 2 at 100 µ M failed to reduce the relaxant effect of trypsin ( Fig. 8b and Table 4 ). Desensitization of both PAR-2 and PAR-1 caused strong suppression This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Our data from signal transduction studies in ddY mice clearly suggest an involvement of both COX-1 and COX-2 isoforms, the MEK-ERK pathway and p38 MAP kinase in the prostanoid-dependent tracheal and bronchial relaxation caused by PAR-2-and PAR-1-activating peptides. Further, our study using PAR-2-knockout mice of C57BL/6 background demonstrates that airway relaxation evoked by SLIGRL-NH 2 and 2f-LIGRL-NH 2 is exclusively mediated by activation of PAR-2, and that the trypsin-evoked airway relaxation involves both PAR-2-dependent and -independent components. The desensitization experiments imply that PAR-2 is involved partially in the trypsin-induced tracheal and bronchial relaxation in ddY and C57BL/6 mice, in agreement with evidence from PAR-2-knockout mice, and that PAR-1 plays a minor or no role in the production of relaxant effect of trypsin in mouse airway. Our data also show significant differences in the sensitivity of the ddY and C57BL/6 trachea and bronchus tissues toward trypsin and PAR-activating peptides.
It has been reported that COX-2, but not COX-1, is involved in the PAR-2 agonist SLIGRL-NH 2 -evoked relaxation in the trachea from CBA/CaH mice (Lan et al., 2001 ) and that PAR-2 and COX-2 proteins are colocalized in basal epithelial cells in the mouse airway (Lan et al., 2004) . However, our present data clearly indicate involvement of both COX isoforms in either This article has not been copyedited and formatted. The final version may differ from this version. in ddY mice by using the potent and highly selective inhibitors, SC-560 for COX-1, and NS-398 or nimesulide for COX-2. The differences between our data and those of Lan et al. (Lan et al., 2001) may possibly be due to differences in the strain and age of mice and effectiveness of the COX inhibitors employed. Nonetheless, our results suggest that both constitutively expressed COX-1 and COX-2 are necessary for prostanoid production following activation of PAR-2 and PAR-1, as described previously in the PAR-1-mediated chloride secretion in intestinal epithelial cells (Buresi et al., 2002) . It is likely that prostanoids formed by one of COX isoforms might enhance activity of the other COX isoform, as described recently (Yamada et al., 2004) . Although the inhibitors for COX-1 and COX-2 were employed at very specific concentrations, we cannot completely rule out the possibility that they affected prostanoid formation through unknown mechanisms other than inhibition of COX-1 and COX-2. In contrast, the pathways for production of arachidonic acid, a substrate for COX, following PAR-2 or PAR-1 stimulation could not be clearly identified by the present study. The finding that BEL produced 40-60% inhibition of the tracheal relaxation caused by activation of PAR-2 or PAR-1, may be in agreement with evidence for involvement of iPLA 2 in PAR-2-mediated contraction of rat urinary bladder (Kubota et al., 2003) . However, the inhibitory effect could be a result of non-specific actions of BEL, because BEL also caused about 30% inhibition of the progtaglandin E 2 -evoked tracheal relaxation. Neither cPLA 2 nor diacylglycerol This article has not been copyedited and formatted. The final version may differ from this version. lipase appear to contribute to the PAR-2-and PAR-1-mediated airway relaxation in ddY mice, although the former enzyme is involved in PAR-1-mediated intestinal chloride secretion (Buresi et al., 2002) . It is most interesting that PD98059 and SB203580, but not genistein or GF109203X, almost completely inhibited the tracheal and bronchial relaxant effects of PAR-2-and PAR-1-activating peptides, suggesting involvement of the MEK-ERK pathway and p38 MAP kinase pathway, but not tyrosine kinase or protein kinase C. Both pathways are considered upstream of prostaglandin formation, as suggested by the lack of the effects of those inhibitors on the relaxation responses to prostaglandin E 2 , known to be responsible for the PAR-mediated tracheal relaxation in mice (Lan et al., 2001) . As the prostanoid-dependent airway relaxation following PAR-2 and PAR-1 stimulation occurs within several seconds and peaks within a few minutes, the underlying mechanisms should involve acute non-transcriptional signals mediated by the MEK-ERK pathway and p38 MAP kinase. There is evidence that activation of either or both of the two pathways participates in smooth muscle contraction (Zheng et al., 1998; Bolla et al., 2002; Harnett and Biancani, 2003) . Our evidence that both the MEK and p38 MAP kinase are upstream of facilitation of prostanoid formation through non-transcriptional mechanisms may be in keeping with the previous report suggesting involvement of MEK in PAR-1-mediated prostanoid-dependent gastric smooth muscle contraction (Zheng et al., 1998) . In certain vascular tissues, p38 MAP kinase can be downstream of the constrictor action of an arachidonate metabolite like thromboxane (Bolla et al., This article has not been copyedited and formatted. The final version may differ from this version. 
It is of note that trypsin-evoked tracheal and bronchial relaxation in mice is mediated only in part by PAR-2, as indicated by the data from PAR-2-knockout mice and the results from receptor desensitization experiments. As the latter experiments also suggest minor or no involvement of PAR-1 in the effect of trypsin, mechanisms other than PAR-2 and PAR-1 should also be considered.
The trypsin-evoked residual airway relaxation independent of PAR-2 and PAR-1 might be explained, reported that CBA/CaH mouse trachea relaxed in response to trypsin at a high concentration, 100 U/ml (Lan et al., 2001) , and that the BALB/c mouse bronchus was greatly dilated by trypsin even at 0.3 U/ml (Cocks et al., 1999a) . The ddY mouse trachea was even less sensitive to trypsin than the C57BL/6 mouse trachea (see Figs. 1 and 7b ). In rats, trypsin at 10 U/ml is incapable of inducing relaxation in the trachea, main bronchus or intrapulmonary bronchus, although a PAR-2-activating This article has not been copyedited and formatted. The final version may differ from this version. 
to understand the pro-and/or anti-inflammatory roles for PARs in pathological conditions. The hypothesis that the trachea is more abundant in trypsin-inhibitory serpins in the epithelium than the bronchus, as described above, may be reasonable, because the tracheal epithelium would be first exposed to exogenous proteinases that inhaled organisms might have. There were also some strain differences between airway relaxation responses to PAR agonists in ddY mice and C57BL/6 mice. In particular, trypsin caused biphasic relaxation in ddY mouse trachea, but relatively simple responses in C57BL/6 mouse trachea. However, our data from desensitization experiments and evidence from PAR-2-knockout mice clearly show that the relaxation responses to trypsin in C57BL/6 mouse trachea also contain two distinct components that are PAR-2-dependent and -independent.
In conclusion, our study suggests novel aspects of PAR-2-and PAR-1-triggered signaling pathways involved in mouse airway relaxation, including MEK and p38 MAP kinase, and provides unequivocal evidence for the involvement of PAR-2 in the tracheal and bronchial relaxation caused by PAR-2-activating peptides and in part for the responses to trypsin. Further, mouse trachea and bronchus appear to show complex distinct sensitivities to PAR-2 agonists including trypsin and PAR-2-activating peptides.
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